Conference Coverage

Deciphering lung cancer biomarkers shrouded in tobacco smoke


 

AT AN AACR/IASLC JOINT CONFERENCE

References

In addition, the exposure biomarkers are not entirely predictive and thus, will need to be combined with multiple DNA adducts and repair if susceptible smokers are to be identified and targeted for state-of-the art cessation approaches and surveillance, he said.

Using high-level mass spectrometry, the researchers have been able to readily measure formaldehyde DNA adducts and tobacco-specific 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB)–releasing DNA adducts in human oral cells. Levels of the HPB adduct were unusually high at 12-45 pmol/mg, which is similar to what is seen in animals when exposed to NNK at a much higher dose than smokers take in.

“So this is a real lead,” said Dr. Hecht, who reported having no relevant conflicts of interest.

pwendling@frontlinemedcom.com

Pages

Recommended Reading

Meta-analysis confirms no OS benefit from antiangiogenics for NSCLC patients
MDedge Internal Medicine
Actionable mutations are highly prevalent in young lung cancer patients
MDedge Internal Medicine
ESC: Heart failure patients have increased cancer incidence
MDedge Internal Medicine
Commentary: Red meat and cancer risk – what your patients should know
MDedge Internal Medicine
Experimental LOXO-101 induces regression in several hard-to-treat cancers
MDedge Internal Medicine
Immune-related events with checkpoint inhibitors are manageable
MDedge Internal Medicine
Hold the checkpoint inhibitors when pneumonitis symptoms occur
MDedge Internal Medicine
Former smokers turning to e-cigarettes
MDedge Internal Medicine
Late risks of breast cancer RT are higher for smokers
MDedge Internal Medicine
Families perceive few benefits from aggressive end-of-life care
MDedge Internal Medicine